Innogenetics completes first US clinical trial on time

Safety and tolerability results of hepatitis B therapeutic vaccine phase I study

05-Apr-2005

Innogenetics announced that it has successfully completed its first clinical study in the United States under Investigational New Drug status (IND).

In April 2004, Innogenetics took over sponsorship of a phase I safety and tolerability study under US IND for the hepatitis B therapeutic vaccine candidate, acquired from Genencor, based on Epimmune's polyepitope technology.

Final results of the phase I study showed that intramuscular injection with either a 0.4-mg or 4-mg dose of this DNA vaccine, administered every 4 weeks over a period of 12 weeks (a total of 4 doses), was safe and well tolerated in all healthy volunteers.

As planned, the next steps in the clinical evaluation program will be to deliver the hepatitis B polyepitope using a DNA vaccine and a viral vector in order to maximize the immune response.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...